-
Eli Lilly's Upcoming Obesity Drugs Highlight Bright Future, Says Optimistic Analyst
Friday, October 6, 2023 - 12:23pm | 307Shares of Eli Lilly And Co (NYSE: LLY) were climbing during Friday's trading session. The stock has been under pressure for the past three months, due to macro uncertainties and not fundamental concerns, according to BofA Securities. The Eli Lilly Analyst: Geoff Meacham reiterated a Buy rating...
-
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
Friday, September 8, 2023 - 11:28am | 391Shares of Gilead Sciences, Inc. (NASDAQ: GILD) are trading higher into Friday’s trading session after Bank of America Securities upgraded the stock, highlighting an underappreciated growth potential in its core HIV business and emerging hematology/oncology franchises. Here’s what...
-
Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another
Wednesday, January 4, 2023 - 2:22pm | 470The health care sector held up relatively well in a difficult year for stocks in 2022. On Wednesday, one analyst adjusted his coverage of two large cap pharmaceutical stocks heading into what could be a volatile 2023. The Analyst: Bank of America analyst Geoff Meacham upgraded Merck & Co Inc (...
-
7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%
Wednesday, September 28, 2022 - 12:10pm | 768Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen Analyst Brian Abrahams maintained an Outperform rating, while raising the price...
-
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal
Monday, August 8, 2022 - 2:50pm | 500Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT). Pfizer said it will pay $68.50 per share for Global Blood, roughly a 42.7% premium to the stock's closing...
-
Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'
Wednesday, June 29, 2022 - 1:32pm | 703The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news, announced Tuesday, June 28, could have a big impact on the share prices of vaccine makers....
-
10 Investor Questions About COVID-19, Answered
Sunday, April 3, 2022 - 10:19am | 759The COVID-19 outbreak has finally subsided in the U.S., but biotech investors still have plenty of lingering questions about the virus and what to expect in the months and years ahead. On Thursday, Bank of America analyst Geoff Meacham answered 10 of the most common COVID-19 questions he's...
-
Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market
Monday, March 21, 2022 - 11:29am | 563After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock. The Moderna Analyst: BofA Securities analyst Geoff Meacham reiterated a Neutral rating on Moderna shares and increased the price target from $170...
-
Why This Analyst Has Increased Confidence In Inovio Pharmaceuticals
Friday, January 21, 2022 - 12:50pm | 264Following the recent pullback in Inovio Pharmaceuticals Inc.’s (NASDAQ: INO) shares, the stock valuation seems to have been stripped of most of the remaining COVID-19 value, according to BofA Securities. The Inovio Pharmaceuticals Analyst: Geoff Meacham upgraded the rating for Inovio...
-
BofA Downgrades CureVac On Limited 2022 Prospects
Friday, January 21, 2022 - 12:28pm | 236There is limited upside from CureVac BV’s (NASDAQ: CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company’s pipeline in 2022, according to BofA Securities. The CureVac Analyst: Geoff Meacham downgraded the rating for CureVac from Neutral to Underperform, while...
-
BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise
Tuesday, January 18, 2022 - 2:28pm | 380Krystal Biotech Inc (NASDAQ: KRYS) shares have potential to nearly double from current levels, according to an analyst at BofA Securities. The Krystal Biotech Analyst: Geoff Meacham initiated coverage of Krystal Biotech shares with a Buy rating and a $110 price target. The Krystal...
-
Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays
Wednesday, January 5, 2022 - 1:18pm | 576An analyst at BofA Securities on Wednesday shared a pair trade idea in the large-cap pharma space. The Biopharma Analyst: Geoff Meacham upgraded Pfizer, Inc. (NYSE: PFE) shares from Neutral to Buy and increased the price target from $59 to $70. The analyst downgraded Regeneron Pharmaceuticals, Inc...
-
How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
Thursday, December 23, 2021 - 4:01pm | 671Pfizer, Inc. (NYSE: PFE) announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration. The Pfizer Analysts: SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer. BofA...
-
3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat
Tuesday, October 19, 2021 - 3:10pm | 453Johnson & Johnson (NYSE: JNJ) shares are higher Tuesday following the release of its third-quarter results. J&J A Bellwether For The Sector: Given the timing of J&J's earnings release and its portfolio breadth, its earnings often serve as a bellwether for the sector, according to...
-
How To Play Moderna Stock Ahead Of Key FDA COVID-19 Booster Shot Ruling
Tuesday, October 12, 2021 - 6:03pm | 463Moderna Inc (NASDAQ: MRNA) shares traded higher by 2% on Tuesday after U.S. Food and Drug Administration scientists opted not to take a stance on the company’s COVID-19 vaccine booster shot. What Happened: In a new 45-page document, the FDA said data suggests two doses of the Moderna COVID-19...